Document is current
Any future updates will be listed below
-
Authors
Demircan, Kamil
Carrasco-Zanini, Julia https://orcid.org/0000-0002-3988-7505
Williamson, Alice
Beuchel, Carl https://orcid.org/0000-0003-3224-3894
Jackson, Linsey
Römisch-Margl, Werner
Hansen, Aleksander L. https://orcid.org/0000-0002-9514-8942
Finer, Sarah https://orcid.org/0000-0002-2684-4653
van Heel, David A. https://orcid.org/0000-0002-0637-2265
,
van Heel, David A.
Kastenmüller, Gabi https://orcid.org/0000-0002-2368-7322
Coghlan, Matthew https://orcid.org/0000-0002-0894-1505
Moeller, Ida
Wareham, Nicholas J. https://orcid.org/0000-0003-1422-2993
Pietzner, Maik https://orcid.org/0000-0003-3437-9963
Langenberg, Claudia https://orcid.org/0000-0002-5017-7344
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 17 March 2026
First Online: 30 April 2026
Competing interests
: L.J., M.C. and I.M. are employees and stockholders of Eli Lilly and Company. Eli Lilly provided no funding for this study and had no influence on the overall analytical plan, conduct or interpretation of main results. L.J. performed analyses of the SURMOUNT-1 trial, according to an analytical plan jointly designed by C.L., K.D., M.C., I.M. and L.J. The other authors declare no competing interests.
